| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net loss | ||||||
-72,183 | -50,171 | -31,523 | - | - | - | - |
Net loss | ||||||
- | - | - | -31,045 | -27,081 | -56,901 | - |
Net loss | ||||||
- | - | - | - | - | - | -3,262 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Impairment of in-process research and development | ||||||
19,000 | - | - | - | - | - | - |
Depreciation and amortization | ||||||
17 | 17 | 11 | 16 | 17 | 33 | - |
Amortization of debt discount recorded as interest expense | ||||||
- | 38 | 206 | 347 | 377 | 1,952 | 36 |
Accretion of marketable securities premium | ||||||
764 | 119 | 185 | -102 | -247 | - | - |
Amortization of right-of-use assets | ||||||
144 | - | - | - | - | - | - |
Stock-based compensation expense | ||||||
9,173 | 8,182 | 5,033 | 3,571 | 2,202 | 17,966 | 655 |
Deferred taxes | ||||||
-2,254 | - | -9,376 | - | - | - | - |
Unrealized foreign exchange gain | ||||||
- | - | - | - | - | - | -22 |
Change in fair value of derivative | ||||||
- | - | - | - | - | 10 | -0 |
Changes in operating assets and liabilities | ||||||
Prepaid expenses and other current assets | ||||||
-723 | 621 | 306 | -372 | 400 | 713 | - |
Prepaid expenses | ||||||
- | - | - | - | - | - | -8 |
Accounts payable | ||||||
517 | 364 | -32 | 107 | 718 | 368 | 522 |
Accrued expenses and other current liabilities | ||||||
2,329 | 369 | 624 | -1,708 | 879 | 112 | -143 |
Operating lease liabilities, current | ||||||
37 | - | - | - | - | - | - |
Accrued collaborative expenses | ||||||
- | - | -2,547 | 2,547 | -1,222 | - | - |
Deferred revenue | ||||||
- | - | 41,175 | - | - | - | - |
Deferred revenue | ||||||
- | - | - | - | - | 1,222 | - |
Other noncurrent assets | ||||||
- | - | 14 | - | - | - | - |
Other noncurrent liabilities | ||||||
- | -0 | 29 | - | -7 | 7 | - |
Operating lease liabilities, noncurrent | ||||||
-172 | - | - | - | - | - | - |
Net cash used in operating activities | ||||||
-43,432 | -41,941 | 3,092 | - | - | - | - |
Cash flows from investing activities: | ||||||
Purchases of marketable securities | ||||||
- | - | 134,525 | - | - | - | - |
Proceeds from the maturity and redemption of marketable securities | ||||||
75,179 | 110,151 | 27,390 | - | - | - | - |
Cash acquired in business combination | ||||||
- | - | - | - | - | 1,167 | - |
Restricted cash | ||||||
- | - | - | - | 44 | 35 | - |
Purchases of equipment | ||||||
- | - | 52 | - | - | 45 | 3 |
Net cash used in operating activities | ||||||
- | - | - | -25,687 | -24,269 | -35,960 | -2,160 |
Proceeds from the maturity and redemption of marketable securities | ||||||
- | - | - | 17,818 | 4,994 | - | - |
Purchase of marketable securities | ||||||
61,094 | 40,661 | - | - | 23,279 | - | - |
Net cash provided (used in) by investing activities | ||||||
14,084 | 69,489 | -107,188 | - | - | - | - |
Cash flows from financing activities: | ||||||
Net cash (used in) provided by investing activities | ||||||
- | - | - | 17,818 | -18,329 | 1,087 | -3 |
Proceeds from sale of common stock in public offering | ||||||
- | - | 44,562 | 57,499 | - | - | - |
Cash acquired in business merger | ||||||
- | - | - | - | - | - | 631 |
Proceeds from issuance of convertible promissory notes | ||||||
- | - | - | - | - | - | 1,300 |
Proceeds from sales of common stock in initial public offering | ||||||
- | - | - | - | - | 31,334 | - |
Costs paid in connection with public offering | ||||||
- | - | 2,944 | 3,832 | - | 3,159 | - |
Repurchase of common stock | ||||||
- | - | 0 | - | - | - | - |
Proceeds from sales of common stock in private placement | ||||||
- | - | - | 999 | 30,999 | 23,706 | 1,850 |
Costs paid in connection with private placements | ||||||
- | - | - | - | 2,466 | 280 | - |
Proceeds from exercise of common stock warrants | ||||||
- | - | 9,356 | 23,392 | - | - | - |
Proceeds from exercise of stock options | ||||||
524 | 655 | 1,130 | 76 | - | - | - |
Proceeds from notes payable | ||||||
- | - | - | - | 10,000 | 1,882 | - |
Costs paid in connection with notes payable | ||||||
- | - | - | - | 195 | - | - |
Repayments of notes payable | ||||||
- | 4,000 | 4,938 | 1,570 | - | 1,882 | - |
Net cash provided by financing activities | ||||||
524 | -3,344 | 47,166 | - | - | - | - |
Net increase (decrease) in cash, cash equivalents and restricted cash | ||||||
-28,822 | 24,203 | -56,928 | - | - | - | - |
Deferred public offering costs included in accounts payable or in accrued expenses and other current liabilities | ||||||
- | - | - | - | - | - | 433 |
Supplemental disclosure of cash flow information | ||||||
Cash paid for interest | ||||||
- | 92 | 436 | - | - | - | - |
Beneficial conversion feature--convertible debt | ||||||
- | - | - | - | - | - | 1,973 |
Cash paid for interest | ||||||
- | - | - | 691 | 616 | 15 | - |
Reconciliation of the Condensed Consolidated Statements of Cash Flows to the Condensed Consolidated Balance Sheets | ||||||
Net (decrease) increase in cash and cash equivalents | ||||||
- | - | - | 68,696 | -4,261 | 16,727 | 1,618 |
Net cash (used in) provided by financing activities | ||||||
- | - | - | 76,566 | 38,337 | 51,600 | 3,781 |
Common stock issued as consideration for business combination | ||||||
- | - | - | - | - | 16,541 | 18,943 |
Accrued expenses and other | ||||||
- | - | - | - | - | 321 | 334 |
ProteoSys milestone payable | ||||||
- | - | - | - | - | 681 | - |
Deferred tax liability | ||||||
- | - | - | - | - | 5,970 | 7,588 |
Convertible promissory notes | ||||||
- | - | - | - | - | - | 680 |
Derivative liability | ||||||
- | - | - | - | - | - | 3 |
Prepaid expenses | ||||||
- | - | - | - | - | 42 | - |
Equipment | ||||||
- | - | - | - | - | 28 | - |
In-process research and development | ||||||
- | - | - | - | - | 15,200 | 19,000 |
Goodwill | ||||||
- | - | - | - | - | 7,076 | 7,918 |
Cash acquired in business merger | ||||||
- | - | - | - | - | 1,167 | 631 |
Conversion of debt and interest to common stock | ||||||
- | - | - | - | - | 2,112 | - |